股本结构
单位：万股
| 公告日期 | 2026-08-12 | 2026-08-12 | 2026-05-27 | 2026-04-28 | 2026-05-12 | 2026-03-23 |
|---|---|---|---|---|---|---|
| 证券总股本 | 658.02 | 658.01 | 657.51 | 598.28 | 578.25 | 578.25 |
| 普通股本 | 658.02 | 658.01 | 657.51 | 598.28 | 578.25 | 578.25 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-08-10 | 2026-06-30 | 2026-05-26 | 2026-04-15 | 2026-03-31 | 2026-03-18 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-08-12 | 658.02 | 未披露 | 定期报告 | 2026-08-10 |
| 2026-08-12 | 658.01 | 未披露 |
更多>>
From March 31, 2026 to June 30, 2026
Exercise of stock options
Issuance of common stock in connection with at-the-market offerings, net of issuance costs
Issuance of common stock in connection with the exercise of prefunded warrants
Issuance of common stock under employee stock purchase plan
|
2026-06-30 |
| 2026-05-27 | 657.51 | 未披露 | 定期报告 | 2026-05-26 |
| 2026-04-28 | 598.28 | 未披露 | 定期报告 | 2026-04-15 |
| 2026-05-12 | 578.25 | 未披露 |
更多>>
From December 31, 2025 to March 31, 2026
Issuance of common stock to settle the liabilities to issue common stock
Issuance of common stock in connection with the exercise of prefunded warrants
Vesting of restricted stock units
Exercise of stock options
|
2026-03-31 |
| 2026-03-23 | 578.25 | 未披露 | 定期报告 | 2026-03-18 |
| 2026-03-12 | 520.00 | 未披露 |
更多>>
a 1-for-14 reverse stock split of the issued shares of the company's common stock
|
2026-03-16 |
| 2026-03-12 | 7350.00 | 未披露 | 定期报告 | 2026-03-12 |
| 2026-02-12 | 7345.72 | 未披露 | 定期报告 | 2026-02-11 |
| 2026-01-05 | 6754.09 | 未披露 | 定期报告 | 2026-01-02 |
| 2025-11-13 | 5250.03 | 未披露 | 定期报告 | 2025-11-11 |
| 2025-10-20 | 5183.05 | 未披露 | 定期报告 | 2025-10-15 |
| 2025-11-13 | 5182.90 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Net loss
Exercise of stock options
Stock-based compensation expense
|
2025-09-30 |
| 2025-08-14 | 5182.79 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of common stock under employee stock purchase plan
Exercise of stock options
|
2025-06-30 |
| 2025-05-08 | 5178.23 | 未披露 | 定期报告 | 2025-05-05 |
| 2025-04-28 | 5177.54 | 未披露 | 定期报告 | 2025-04-11 |
| 2025-05-08 | 5177.53 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of common stock in connection with the AbbVie stock purchase agreement, net of issuance costs
Issuance of common stock in connection with at-the-market offerings, net of issuance costs
Vesting of restricted stock units
Exercise of stock options
|
2025-03-31 |
| 2025-03-11 | 5177.37 | 未披露 | 定期报告 | 2025-03-03 |
| 2025-03-11 | 4575.68 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of common stock and prefunded warrants in connection with the Gilead stock purchase agreement, net of issuance costs
Issuance of common stock and prefunded warrants in connection with a private placement, net of issuance costs
Issuance of common stock in connection with at-the-market offerings, net of issuance costs
Issuance of common stock under employee stock purchase plan
Vesting of restricted common stock
Exercise of stock options
|
2024-12-31 |
| 2024-12-19 | 4571.81 | 未披露 |
更多>>
the Company issued and sold an aggregate of 1,759,978 shares of common stock
|
2024-12-18 |
| 2024-11-07 | 4395.81 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Exercise of stock options
|
2024-09-30 |
| 2024-08-08 | 4395.25 | 未披露 | 定期报告 | 2024-08-01 |
| 2024-08-08 | 4395.19 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of common stock in connection with at-the-market offerings, net of issuance costs
Exercise of stock options
Issuance of common stock and prefunded warrants in connection with a private placement, net of issuance costs
Issuance of common stock under employee stock purchase plan
Issuance of common stock and prefunded warrants in connection with the Gilead stock purchase agreement, net of issuance costs
Vesting of restricted common stock
|
2024-06-30 |
| 2024-05-14 | 3691.24 | 未披露 | 定期报告 | 2024-05-10 |
| 2024-04-25 | 3691.22 | 未披露 | 定期报告 | 2024-04-15 |
| 2024-05-14 | 3447.26 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of common stock in connection with the Gilead stock purchase agreement, net of issuance costs
Vesting of restricted common stock
|
2024-03-31 |
| 2024-04-01 | 3447.35 | 未披露 | 定期报告 | 2024-03-28 |
| 2024-04-01 | 2760.76 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Vesting of restricted common stock
Exercise of stock options
Issuance of common stock under employee stock purchase plan
|
2023-12-31 |
| 2023-11-09 | 2754.20 | 未披露 | 定期报告 | 2023-11-07 |
| 2023-11-09 | 2752.89 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Exercise of stock options
Vesting of restricted common stock
|
2023-09-30 |
| 2023-08-14 | 2753.96 | 未披露 | 定期报告 | 2023-08-04 |
| 2023-08-14 | 2751.89 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Exercise of stock options
Vesting of restricted common stock
Issuance of common stock under employee stock purchase plan
|
2023-06-30 |
| 2023-05-09 | 2747.07 | 未披露 | 定期报告 | 2023-05-05 |
| 2023-04-25 | 2747.05 | 未披露 | 定期报告 | 2023-04-14 |
| 2023-05-09 | 2743.98 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Exercise of stock options
Vesting of restricted common stock
|
2023-03-31 |
| 2023-03-02 | 2747.17 | 未披露 | 定期报告 | 2023-02-24 |
| 2023-03-02 | 2742.54 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Exercise of stock options
Vesting of restricted common stock
|
2022-12-31 |
| 2022-11-09 | 2747.16 | 未披露 | 定期报告 | 2022-11-04 |
| 2022-11-09 | 2740.71 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Vesting of restricted common stock
|
2022-09-30 |
| 2022-08-09 | 2747.16 | 未披露 | 定期报告 | 2022-08-01 |
| 2022-08-09 | 2739.18 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Vesting of restricted common stock
|
2022-06-30 |
| 2022-04-26 | 2747.16 | 未披露 | 定期报告 | 2022-04-14 |
| 2022-05-12 | 2737.65 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Vesting of restricted common stock
Exercise of stock options
|
2022-03-31 |
| 2022-03-01 | 2746.90 | 未披露 | 定期报告 | 2022-02-15 |
| 2022-03-01 | 2735.84 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of Series B convertible preferred stock, net of issuance costs of $50,000
Issuance of Series C convertible preferred stock, net of issuance costs of $314,000
Conversion of convertible preferred stock into common stock upon initial public offering
Issuance of common stock upon initial public offering, net of issuance costs of $13,547,000
Vesting of restricted common stock
Exercise of stock options
|
2021-12-31 |
| 2021-12-02 | 2746.89 | 未披露 | 定期报告 | 2021-11-25 |
| 2021-12-02 | 2743.21 | 未披露 |
更多>>
1.Xilio issued and sold an additional 766,106 shares of common stock at a public offering price of $16.00 per share pursuant to the partial exercise by the
underwriters of their option to purchase additional shares.
2.The number of shares of common stock to be outstanding after this offering is based on 26,666,008 shares of common stock outstanding as of October 22, 2021
|
2021-11-01 |
| 2021-10-22 | 2666.60 | 未披露 |
更多>>
1.Common stock offered by company 7,353,000 shares
2.The number of shares of common stock to be outstanding after this offering is based on 914,760 shares of common stock outstanding as of September 30, 2021
|
2021-10-22 |
From March 31, 2026 to June 30, 2026
Exercise of stock options
Issuance of common stock in connection with at-the-market offerings, net of issuance costs
Issuance of common stock in connection with the exercise of prefunded warrants
Issuance of common stock under employee stock purchase plan
From December 31, 2025 to March 31, 2026
Issuance of common stock to settle the liabilities to issue common stock
Issuance of common stock in connection with the exercise of prefunded warrants
Vesting of restricted stock units
Exercise of stock options
a 1-for-14 reverse stock split of the issued shares of the company's common stock
From June 30, 2025 to September 30, 2025
Net loss
Exercise of stock options
Stock-based compensation expense
From March 31, 2025 to June 30, 2025
Issuance of common stock under employee stock purchase plan
Exercise of stock options
From December 31, 2024 to March 31, 2025
Issuance of common stock in connection with the AbbVie stock purchase agreement, net of issuance costs
Issuance of common stock in connection with at-the-market offerings, net of issuance costs
Vesting of restricted stock units
Exercise of stock options
From December 31, 2023 to December 31, 2024
Issuance of common stock and prefunded warrants in connection with the Gilead stock purchase agreement, net of issuance costs
Issuance of common stock and prefunded warrants in connection with a private placement, net of issuance costs
Issuance of common stock in connection with at-the-market offerings, net of issuance costs
Issuance of common stock under employee stock purchase plan
Vesting of restricted common stock
Exercise of stock options
the Company issued and sold an aggregate of 1,759,978 shares of common stock
From June 30, 2024 to September 30, 2024
Exercise of stock options
From March 31, 2024 to June 30, 2024
Issuance of common stock in connection with at-the-market offerings, net of issuance costs
Exercise of stock options
Issuance of common stock and prefunded warrants in connection with a private placement, net of issuance costs
Issuance of common stock under employee stock purchase plan
Issuance of common stock and prefunded warrants in connection with the Gilead stock purchase agreement, net of issuance costs
Vesting of restricted common stock
From December 31, 2023 to March 31, 2024
Issuance of common stock in connection with the Gilead stock purchase agreement, net of issuance costs
Vesting of restricted common stock
From December 31, 2022 to December 31, 2023
Vesting of restricted common stock
Exercise of stock options
Issuance of common stock under employee stock purchase plan
From June 30, 2023 to September 30, 2023
Exercise of stock options
Vesting of restricted common stock
From March 31, 2023 to June 30, 2023
Exercise of stock options
Vesting of restricted common stock
Issuance of common stock under employee stock purchase plan
From December 31, 2022 to March 31, 2023
Exercise of stock options
Vesting of restricted common stock
From December 31, 2021 to December 31, 2022
Exercise of stock options
Vesting of restricted common stock
From June 30, 2022 to September 30, 2022
Vesting of restricted common stock
From March 31, 2022 to June 30, 2022
Vesting of restricted common stock
From December 31, 2021 to March 31, 2022
Vesting of restricted common stock
Exercise of stock options
From December 31, 2020 to December 31, 2021
Issuance of Series B convertible preferred stock, net of issuance costs of $50,000
Issuance of Series C convertible preferred stock, net of issuance costs of $314,000
Conversion of convertible preferred stock into common stock upon initial public offering
Issuance of common stock upon initial public offering, net of issuance costs of $13,547,000
Vesting of restricted common stock
Exercise of stock options
1.Xilio issued and sold an additional 766,106 shares of common stock at a public offering price of $16.00 per share pursuant to the partial exercise by the
underwriters of their option to purchase additional shares.
2.The number of shares of common stock to be outstanding after this offering is based on 26,666,008 shares of common stock outstanding as of October 22, 2021
1.Common stock offered by company 7,353,000 shares
2.The number of shares of common stock to be outstanding after this offering is based on 914,760 shares of common stock outstanding as of September 30, 2021